Céspedes QMC, León BYL, Vinent CAM, Edwards SS

Language: Spanish
References: 19
Page: 199-207
PDF size: 252.01 Kb.

ABSTRACT

A descriptive, cross-sectional and prospective study of 201 patients with breast cancer assisted in the Chemotherapy Service of "ConradoBenítezGarcía" Teaching Provincial Oncological Hospital in Santiago de Cuba was carried out during a year (from June, 2013 to the same month of 2014), in order to characterize them and to determine neutropenia as adverse reaction to the treatment. The information was analyzed statistically by means of the percentage calculation and the test Chi squared test, with which it was obtained that 82 patients suffered neutropenia (40.7%) in whom the age group 41- 60 years prevailed (50.0%), the clinical stage II of the malignant tumor (65.8%) and just one neutropenia episode (90.2%). As for the patients diagnosed with neutropenia, 91 episodes were registered, with higher frequency of the moderated degrees (52.7%) and mild (39.5%), and a favorable reaction to the stimulating factor of human granulocytes colonies 81.8% of them. Lastly, the neutropenia existence as adverse effect to the cytostatic drugs in almost 50% of the patients was demonstrated, as well as the beneficial result of the stimulating factor in them; however, there was no association between the different combinations of cytostatic drugs and the episodes and neutropenia degrees.

REFERENCES

1. Alfonso Galbán P, Alonso Orta I, Alonso Carbonell L, Calvo Barbados DM, Cruz Barrios MA, Pérez Peña J, et al. Formulario de Medicamentos Cuba. La Habana: Editorial Ciencias Médicas; 2011.

2. González García MI, Salvador Garrido P, Piñeiro Iglesias MJ, Dominguez Hernández DV, Martínez Losada M. Protocolos de Vigilancia Sanitaria Específica. Agentes citostáticos Ministerio Salubridad y consumo. Madrid: Ministerio de Sanidad y Consumo; 2003 [citado 6 Sep 2013].

3. Céspedes Quevedo MC, Segura López D, Martínez Rodríguez E, Cobas Ramos Z, Bronfield Caballero D. Efecto del factor estimulante de colonias de granulocitos en pacientes con cáncer. MEDISAN. 2013 [citado 6 Jun 2014]; 17(1).

4. Lami Casaus L, Arbesú Michelena MA, Alsina Sarmiento S, Brito Iglesia R. Aparición de episodios de neutropenia febril tras la quimioterapia citostática en el paciente oncológico. Rev Cubana Farm. 2009 [citado 6 Jun 2014]; 43(4).

5. Mendoza Hernández I, Cachimaille Benavides Y, Guerra Chaviano PP, Robaina García M, Damaso Fernández J, Wilford de León M, et al. Impacto en la asistencia médica cubana de la extensión nacional del ior® LeukoCIM a través de ensayos clínicos. Rev Cubana Farm. 2010 [citado 10 Ago 2014]; 44(Sup. 2).

6. Pettengell R, Schwenkglenks M, Bacon P, Lawrinson S, Duehrsen U. Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated análisis. Hematol Oncol. 2011; 29(4): 117-84.

7. Santibáñez Morales A, Bagnarello F, Sánchez Serrano AP, de la Jara JF. Factor estimulante de colonias de granulocitos y su efecto en el ámbito reproductivo. Rev Mex Med Reprod. 2012; 4(4): 147-52.

8. Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin. 2011; 27(1): 79-86.

9. Herbst C, Naumann F, Kruse EB, Monsef I, Bohlius J, Schulz H, Engert A. Profilaxis con antibióticos y G-CSF para prevenir las infecciones y mejorar la supervivencia de los pacientes con cáncer que reciben quimioterapia. Biblioteca Cochrane Plus. 2014 [citado 29 Ago 2014]; (1).

10. Cuba. Ministerio de Salud Pública. Dirección Nacional de Registro Médicos y Estadísticos de Salud. Anuario Estadístico de Salud 2012. La Habana: MINSAP; 2013 [citado 6 Jun 2014].

11. Suardíaz Pareras J, Cruz Rodríguez C, Colina Rodríguez A. Laboratorio clínico. La Habana: Editorial Ciencias Médicas; 2004.

12. Pérez Ruiz L, Fernández Águila JD, Ramos Cedeño AM. Factor estimulante de colonias de granulocitos en el tratamiento ambulatorio de la neutropenia posterior a la quimioterapia. Rev Panam Salud Publica. 2009 [citado 10 Ago 2014]; 26(3).

13. Rondón Ayala JA, Concepción Pérez ML, Negrín Marrero R, Ruiz Calabuch H, Rodríguez Castañeda H. Evaluación del tratamiento con el factor estimulante de colonias granulocíticas en pacientes oncológicos con riesgo de neutropenia. Hospital General de Sancti Spíritus. Año 2008 -2009. Gaceta Médica Espirituana. 2009 [citado 10 Ago 2014]; 11(3).

14. Loibl S, Mueller V, von Minckwitz G, Bettina C, Koehne CH, Kremers S, et al. Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients within node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer. 2011; 19(11): 1789-95.

15. Zwick C, Hartmann F, Zeynalova S, Pöschel V, Nickenig C, Reiser M, et al. Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol. 2011; 22(8): 1872-7.

16. Arencibia Núñez A. Neutropenia febril: convertir el bajo riesgo en cero riesgo. Rev Cubana Hematol Inmunol Hemoter. 2009 [citado 3 Jun 2014]; 25(2).

17. Hershman DL, Wilde ET, Wright JD, Buono DL, Kalinsky K, Malin JL. Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol. 2012; 30(8): 806-12.

18. Paba C, Sachdev J, Kronish L, Jahanzeb M, Waheed S. Empiric dose reduction of pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2008; 26(15): 20636.

19. Gregory SA, Schwartzberg LS, Sierra J, Vogel C. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Commun Oncol. 2010 [citado 29 Ago 2014]; 7(7): 297-308.